Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study

[1] Anderson GD(2005)Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach Clin Pharmacokinet 44 989-1008

[2] Gilbert EM(2015)Antiretroviral pharmacokinetics in pregnant women Pharmacotherapy 35 838-855

[3] Darin KM(2014)Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily HIV Med. 15 50-56

[4] Scarsi KK(2016)Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women HIV Med. 17 643-652

[5] Zorrilla CD(2010)Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women J Acquir Immune Defic Syndr 55 345-350

[6] Wright R(2012)Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum J Acquir Immune Defic Syndr 59 245-252

[7] Osiyemi OO(2016)Pharmacokinetics of total and unbound etravirine in HIV-1-infected pregnant women J Acquir Immune Defic Syndr 73 268-274

[8] Crauwels HM(2016)Etravirine pharmacokinetics in HIV-infected pregnant women Front Pharmacol. 7 239-1341

[9] Kakuda TN(2017)Lowered rilpivirine exposure during the third trimester of pregnancy in human immunodeficiency virus type 1-infected women Clin Infect Dis 65 1335-296

[10] Ryan B(2016)Pharmacokinetics of rilpivirine in HIV-infected pregnant women J Acquir Immune Defic Syndr 72 289-42

[1] Anderson GD(2005)Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach Clin Pharmacokinet 44 989-1008

[2] Gilbert EM(2015)Antiretroviral pharmacokinetics in pregnant women Pharmacotherapy 35 838-855

[3] Darin KM(2014)Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily HIV Med. 15 50-56

[4] Scarsi KK(2016)Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women HIV Med. 17 643-652

[5] Zorrilla CD(2010)Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women J Acquir Immune Defic Syndr 55 345-350

[6] Wright R(2012)Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum J Acquir Immune Defic Syndr 59 245-252

[7] Osiyemi OO(2016)Pharmacokinetics of total and unbound etravirine in HIV-1-infected pregnant women J Acquir Immune Defic Syndr 73 268-274

[8] Crauwels HM(2016)Etravirine pharmacokinetics in HIV-infected pregnant women Front Pharmacol. 7 239-1341

[9] Kakuda TN(2017)Lowered rilpivirine exposure during the third trimester of pregnancy in human immunodeficiency virus type 1-infected women Clin Infect Dis 65 1335-296

[10] Ryan B(2016)Pharmacokinetics of rilpivirine in HIV-infected pregnant women J Acquir Immune Defic Syndr 72 289-42